## **Pediatric Thoracic - Heart Transplant Recipient Registration Worksheet**

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information		
Name:	D	OB:
SSN:	В	irth sex:
HIC:	T) Ti	ransplant Date and me:
State of Permanent Residence: *		
Permanent Zip: *	-	
Provider Information		
Recipient Center:		
Physician Name:*		
Physician NPI#:*		
Surgeon Name: *		
Surgeon NPI#:*		
Donor Information		
UNOS Donor ID #:		
Recovering OPO:		
Donor Type:		
Patient Status		
Primary Diagnosis: *		
Specify:		
Date: Last Seen, Retransplanted or Death*		
Patient Status: *	CLIVING	
	DEAD	
	RETRANSPLANTED	
Primary Cause of Death:		
Specify:		
Contributory Course of Double		
Contributory Cause of Death:		
Specify:		
Contributory Cause of Death:		
Specify:		
Transplant Hospitalization:		
Date of Admission to Tx Center:*		
Date of Discharge from Tx Center:		
Clinical Information : PRETRANSPLANT		
Medical Condition at time of transplant: $\ast$	OIN INTENSIVE CARE	UNIT
	HOSPITALIZED NOT	IN ICU
	ONOT HOSPITALIZED	
Patient on Life Support: *	OYES ONO	
Copyright © 2023 United Network for	r Organ Sharing. All rights	reserved. OPTN use only. 091423

	☐ Extra Corporeal Membrane	Oxygenation	
	☐ Intra Aortic Balloon Pump		
	Prostaglandins		
	☐ Intravenous Inotropes		
	☐ Inhaled NO		
	Ventilator		
Specify:	Other Mechanism		
Patient on Ventricular Assist Device *			
Patient on Ventricular Assist Device *	ONONE		
	OLVAD		
	RVAD		
	Стан		
	OLVAD+RVAD		
Life Support: VAD Brand1			
Specify:			
Life Support: VAD Brand2			
Specify:			
Functional Status: *			
Comitive Development	0		
Cognitive Development: *	Definite Cognitive delay,		
	Probable Cognitive delay	y/impairment	
	Questionable Cognitive of	delay/impairment	
	No Cognitive delay/impa	airment	
	Not Assessed		
Motor Development: *	Opefinite Motor delay/im	pairment	
	Probable Motor delay/in	npairment	
	Questionable Motor dela	ny/impairment	
	No Motor delay/impairm	nent	
	Not Assessed		
Academic Progress:*	Within One Grade Level	of Peers	
	Delayed Grade Level		
	Special Education		
	Not Applicable, too your	ng for school/ High School g	raduate or GED
	Status Unknown		
Academic Activity Level:*			
Academic Activity Level: *	Full academic load		
	Reduced academic load		
	Ounable to participate in	academics due to disease or	r condition
	Unable to participate reg	gularly due to dialysis	
	Not Applicable, too your	ng for school/ High School g	raduate or GED
	Status Unknown		
Source of Payment:			
Primary: *			
Specify:			
Height Measurement Date:			
Height: *	ft. in.	cm	ST=
Weight Measurement Date:			
Weight: *	lbs	kg	ST=
BMI:	kg/m <sup>2</sup>	_	
Previous Transplants:			
Previous Transplant Organ	Previous Transplant Date	Previous Transplant Graft Fa	ail Date

The three most recent transplants are listed here. Please contace emailing unethelpdesk@unos.org.	t the UNet Help Desk to confirm more than three previous transplants by calling 800-978-4334 or by
Viral Detection:	
HIV Serostatus: *	Positive
	Negative
	Not Done
	UNK/Cannot Disclose
CMV Status*	Positive
	Negative
	Not Done
	OUNK/Cannot Disclose
HBV Surface Antibody Total *	Positive
	Negative
	ONot Done
	OUNK/Cannot Disclose
HBV Core Antibody: <b>*</b>	Positive
	○ Negative
	Not Done
	UNK/Cannot Disclose
HBV Surface Antigen: *	Positive
	○ Negative
	Not Done
	UNK/Cannot Disclose
HCV Serostatus: <b>∗</b>	Positive
	○ Negative
	Not Done
	UNK/Cannot Disclose
EBV Serostatus: *	Positive
	Negative
	Not Done
	UNK/Cannot Disclose
Vaccination Status:	
Did the recipient receive Hepatitis B vaccines prior to transplant?: $*$	YES NO UNK
Reason not vaccinated:	Immunity
	Medical precaution
	Time constraints
	Patient objection
	Product out of stock
	Other, specify
Specify:	
NAT Results:	
HIV NAT: *	Positive
	Negative
	Not Done
	UNK/Cannot Disclose
Copyright © 2023 United Network for O	rgan Sharing. All rights reserved. OPTN use only. 091423

HBV NAI:∗		○ Positive			
		Negative			
		Not Done			
		<b>UNK/Cannot Disclos</b>	e		
HCV NAT: <b>∗</b>		Positive			
		<b>Negative</b>			
		Not Done			
		<b>UNK/Cannot Disclos</b>	e		
Most Recent Hemodynamics: PA (sys)mm/Hg: *				ST=	Inotropes/Vasodilators:  YES NO
PA(dia) mm/Hg:*				ST=	YES NO
PA(mean) mm/Hg:*				ST=	OYES ONO
PCWP mm/Hg:∗				ST=	OYES ONO
CO L/min: *				ST=	YES NO
Cardiac Index					
Most Recent Serum Creatinine:*			mg/dl	ST=	
Most Recent Total Bilirubin: *			mg/dl	ST=	
Chronic Steroid Use: *		YES NO UNK			
Events occurring between listing and transplant: Transfusions: *	:	OYES ONO OUNK			
Infection Requiring IV Therapy within 2 wks price	or to Tx:	YES NO UNK			
*					
Dialysis: ∗		YES NO UNK			
Episode of Ventilatory Support: *		YES NO UNK			
If yes, indicate most recent timeframe:		At time of transplan	t		
		Within 3 months of			
		>3 months prior to			
Daine Theoretic Common although a mineral to the control of the co			•		
Prior Thoracic Surgery other than prior transplar	nt:*	YES NO UNK			
If yes, number of prior sternotomies:		Ounknown if there we	ere prior sternot	comies	
		<b>o</b>			
		<b>1</b>			
		<b>2</b>			
		<b>3</b>			
		<b>4</b>			
		<b>5</b> +			
		Unknown number of	prior sternoton	nies	
If yes, number of prior thoracotomies:		Ounknown if there we	ere prior thoraco	otomies	
		<b>0</b>			
		<b>1</b>			
		<b>2</b>			
		<b>3</b>			
		<b>4</b>			
		<b>5</b> +			
		Ounknown number of	prior thoracoto	mies	
Copyright © 2023 United Networ	k for Org	an Sharing. All rights	s reserved. Ol	PTN use only. (	091423

	OYES ONO OUNK
If yes, palliative surgery:	YES NO UNK
If yes, corrective surgery:	YES NO UNK
If yes, single ventricular physiology:	YES NO UNK
Pretransplant Titer Information:	
Most Recent Anti-A Titer:	Sample Date:
Most Recent Anti-B Titer:	Sample Date:
Clinical Information : TRANSPLANT PROCEI	DURE
Multiple Organ Recipient	
Were extra vessels used in the transplant procedure:	
Procedure Type:	OHeart
	OHeart Lung
Heart Procedure:*	Orthotopic Bicaval
	Orthotopic Traditional Orthotopic Total (Bicaval, PV)
	Heterotopic
Total Organ Preservation Time From Cross Clamp to In Sit	u Reperfusion (include warm and cold time):
Heart, Heart-Lung:	min ST=
Organ Check-in Information:	
Heart Check-In Date: Time: Date and Time:	Military time Time Zone:
Clinical Information : POST TRANSPLANT	
Graft Status:*	Functioning Failed
If death is indicated for the recipient, and the death was a result of	of some other factor unrelated to graft failure, select Functioning.
Date of Graft Failure:	
Primary Cause of Graft Failure:	Primary Non-Function
Primary Cause of Graft Failure:	Acute Rejection
Primary Cause of Graft Failure:	Acute Rejection  Chronic Rejection/Atherosclerosis
	Acute Rejection
Primary Cause of Graft Failure:  Specify: PostTransplant Titer Information:	Acute Rejection  Chronic Rejection/Atherosclerosis
Specify:	Acute Rejection  Chronic Rejection/Atherosclerosis
Specify: PostTransplant Titer Information:	Acute Rejection  Chronic Rejection/Atherosclerosis  Other, Specify
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date:
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours:	Acute Rejection  Chronic Rejection/Atherosclerosis  Other, Specify  Sample Date:  Sample Date:
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours:  Is Primary Graft Dysfunction (PGD) present: *	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date: Sample Date:
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours:  Is Primary Graft Dysfunction (PGD) present: *  PGD - Left Ventricular Dysfunction (PGD-LV):*	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date: Sample Date:  YES NO UNK YES NO UNK
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours:  Is Primary Graft Dysfunction (PGD) present: *  PGD - Left Ventricular Dysfunction (PGD-LV): *  PGD - Right Ventricular Dysfunction (PGD-RV): *	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date: Sample Date:  YES NO UNK YES NO UNK YES NO UNK
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours:  Is Primary Graft Dysfunction (PGD) present: *  PGD - Left Ventricular Dysfunction (PGD-LV): *  PGD - Right Ventricular Dysfunction (PGD-RV): *	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date: Sample Date:  YES NO UNK YES NO UNK YES NO UNK Severely Depressed LV Function (EF < 30%)
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours:  Is Primary Graft Dysfunction (PGD) present: *  PGD - Left Ventricular Dysfunction (PGD-LV): *  PGD - Right Ventricular Dysfunction (PGD-RV): *	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date: Sample Date:  YES NO UNK YES NO UNK YES NO UNK Severely Depressed LV Function (EF <30%) Moderately Depressed LV Function (EF >=30% - <40%)
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours:  Is Primary Graft Dysfunction (PGD) present: *  PGD - Left Ventricular Dysfunction (PGD-LV): *  PGD - Right Ventricular Dysfunction (PGD-RV): *	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date: Sample Date:  YES NO UNK YES NO UNK YES NO UNK Severely Depressed LV Function (EF < 30%) Moderately Depressed LV Function (EF >= 30% - <40%) Mildly Depressed LV Function (EF >= 40% - <50%)
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours:  Is Primary Graft Dysfunction (PGD) present: *  PGD - Left Ventricular Dysfunction (PGD-LV): *  PGD - Right Ventricular Dysfunction (PGD-RV): *	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date:  Sample Date:  YES NO UNK  YES NO UNK  YES NO UNK  Severely Depressed LV Function (EF <30%) Moderately Depressed LV Function (EF >=30% - <40%) Mildly Depressed LV Function (EF >=40% - <50%) Normal LV Function (EF >=50%)
Specify:  PostTransplant Titer Information:  Most Recent Anti-A Titer:  Most Recent Anti-B Titer:  Primary Graft Dysfunction at 24 hours: Is Primary Graft Dysfunction (PGD) present: *  PGD - Left Ventricular Dysfunction (PGD-LV): *  PGD - Right Ventricular Dysfunction (PGD-RV): *  Left Ventricular Ejection Fraction (LVEF): *  Hemodynamics at 24 hours:  Right Atrial (RA) Pressure: *	Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify  Sample Date:  Sample Date:  YES NO UNK  YES NO UNK  YES NO UNK  Severely Depressed LV Function (EF <30%) Moderately Depressed LV Function (EF >=30% - <40%) Mildly Depressed LV Function (EF >=40% - <50%) Normal LV Function (EF >=50%)

Pulmonary Capillary Wedge Pressure (PCWP): *	mm/Hg	ST=
Left Atrial (LA) Pressure: *	mm/Hg	ST=
Pulmonary Artery (PA) Systolic Pressure:*	mm/Hg	ST=
Pulmonary Artery (PA) Diastolic Pressure:*	mm/Hg	ST=
Cardiac Output (CO):*	L/min	ST=
Patient on Life Support at 24 hours: *	OYES ONO	
	Extra Corporeal Membrane Oxyge	enation
	☐ Intra Aortic Balloon Pump	
	☐ Inhaled NO	
Patient on Ventricular Assist Device at 24 hours: *	ONONE	
	OLVAD	
	ORVAD	
	Отан	
	OLVAD+RVAD	
	CLVAD+RVAD	
VAD Brand1:*		
Specify: *		
VAD Brand2: *		
Specify: *		
Epoprostenol at 24 hours following transplant:*	YES NO UNK	
notrope Support at 24 hours:		
Epinephrine: *		mcg/kg/min
Milrinone: *		mcg/kg/min
Dobutamine: *		mcg/kg/min
Dopamine:*		mcg/kg/min
		meg/kg/min
/asopressors at 24 hours:	0	
evo (Norepinephrine - Levophed):*	YES ONO OUNK	
Unit of measure: *	Omcg/min	
	Omcg/kg/min	
Dosage: *		mcg/min
Dosage: *		mcg/kg/min
leo (Phenylephrine – Neosynephrine):*	OYES ONO OUNK	
Unit of measure:*		
onit of measure: *	Omcg/min	
	Omcg/kg/min	
Dosage: *		mcg/min
Dosage *		mcg/kg/min
/aso (Vasopressin − Pitressin)*		unit/min
rimary Graft Dysfunction at 72 hours		
s Primary Graft Dysfunction (PGD) present: *	YES NO UNK	
PGD - Left Ventricular Dysfunction (PGD-LV):*	YES ONO OUNK	
PGD - Right Ventricular Dysfunction (PGD-LV):*		
rep - right vehicleal bystunction (PGD-LV):*	YES ONO OUNK	
eft Ventricular Ejection Fraction (LVEF):*	Severely Depressed LV Function (I	EF <30%)
	Moderately Depressed LV Function	n (EF >=30% - <40%)
	Mildly Depressed LV Function (EF	>=40% - <50%)
	Normal LV Function (EF >=50%)	
	Unknown	
Hemodynamics at 72 hours:		
Right Atrial (RA) Pressure: *	mm/Hg	ST=
Pulmonary Capillary Wedge Pressure (PCWP): * Copyright © 2023 United Network for C	mm/Hg  Drgan Sharing All rights reserved (	ST= OPTN use only 091423

Left Atrial (LA) Pressure: *	mm/Hg	ST=
Pulmonary Artery (PA) Systolic Pressure: ∗	mm/Hg	ST=
Pulmonary Artery (PA) Diastolic Pressure: *	mm/Hg	ST=
Cardiac Output (CO): *	L/min	ST=
Patient on Life Support at 72 hours?*	OYES ONO	
	☐ Extra Corporeal Membrane O	xvgenation
	☐ Intra Aortic Balloon Pump	7,3
	☐ Inhaled NO	
Patient on Ventricular Assist Device at 72 hours: *		
Patient on Ventricular Assist Device at 72 nours: *	ONONE	
	OLVAD	
	ORVAD	
	СТАН	
	OLVAD+RVAD	
VAD Brand1:*		
Specify: *		
VAD Brand2: *		
Specify: *		
Epoprostenol at 72 hours following transplant:*	OYES ONO OUNK	
Inotrope Support at 72 hours:		
Epinephrine: *		mcg/kg/min
Milrinone: *		mcg/kg/min
Dobutamine: *		mcg/kg/min
Dopamine:*		mcg/kg/min
Vasopressors at 72 hours:		
Levo (Norepinephrine - Levophed):*	YES NO UNK	
Unit of measure: *	Omcg/min	
	Omcg/kg/min	
	onicg/ kg/ illiii	
Dosage: *		mcg/min
Dosage: *		mcg/kg/min
Neo (Phenylephrine – Neosynephrine): *	YES NO UNK	
Unit of measure: *	Omcg/min	
	Omcg/kg/min	
Dosage: *		mcg/min
Dosage: *		mcg/kg/min
Vaso (Vasopressin − Pitressin)*		unit/min
Events Prior to Discharge:		
Stroke: *	OYES ONO OUNK	
Dialysis: *	OYES ONO OUNK	
Permanent Pacemaker: *	YES NO UNK	
Did patient have any acute rejection episodes between	Yes, at least one episode trea	ited with anti-rejection agent
transplant and discharge: *	Yes, none treated with additi	onal anti-rejection agent
	ONo	
Immunosuppressive Information	Overa Over	
Are any medications given currently for maintenance or anti-rejection: $\pmb{\ast}$	YES NO	
Immunosuppressive Medications		
View Immunosuppressive Medications		
Copyright © 2023 United Network for Org	gan Sharing. All rights reserve	ed. OPTN use only. 091423

## **Definitions Of Immunosuppressive Medications**

For each of the immunosuppressive medications listed, select **Ind** (Induction), **Maint** (Maintenance) or **AR** (Anti-rejection) to indicate all medications that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank

Induction (Ind) immunosuppression includes all medications given for a <u>short finite period</u> in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it <u>will not</u> be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as anti-rejection therapy if used for this reason. For each induction medication indicated, write the <u>total number of days the drug was actually administered</u> in the space provided. For example, if Simulect was given in 2 doses a week apart then the total number of days would be 2, even if the second dose was given after the patient was discharged.

**Maintenance (Maint)** includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them <u>long-term</u> (example: prednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or Thymoglobulin). When switching maintenance drugs (example: from tacrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.** 

Drug used for induction, acute rejection, or maintenance					
Drag about to manufacturity assess regions in the manufacturity assessment of the manufacturity as a second of the man	Ind.	Days	ST	Maint	AR
Steroids (prednisone, methylprednisolone, Solumedrol, Medrol)					
Down and for industry and the state of					
Drugs used for induction or acute rejection	Ind.	Days	ST	Maint	AR
Atgam					
Campath (alemtuzumab)					
Cytoxan (cyclophosphamide)					
Methotrexate (Folex PFS, Mexate-AQ, Rheumatrex)					
Rituxan (rituximab)					
Simulect (basiliximab)					
Thymoglobulin					
Drugs primarily used for maintenance	Ind.	Days	ST	Maint	AR
Cyclosporine, select from the following:		/-			
- Gengraf					
- Neoral					
- Sandimmune					
- Generic cyclosporine					
Imuran (azathioprine, AZA)					
Leflunomide (LFL)					
Mycophenolic acid, select from the following:					
- CellCept (MMF)					
- Generic MMF (generic CellCept)					
- Myfortic (mycophenolic acid)					
- Generic Myfortic (generic mycophenolic acid)					
mTOR inhibitors, select from the following:					
- Rapamune (sirolimus)					
- Generic sirolimus					
- Zortress (everolimus)					
Nulojix (belatacept)					
Tacrolimus, select from the following:					

Copyright © 2023 United Network for Organ Sharing. All rights reserved. OPTN use only. 091423

- Astagraf XL (extended release tacrolimus)					
- Envarsus XR (tacrolimus XR)					
- Prograf (tacrolimus)					
- Generic tacrolimus (generic Prograf)					
Other drugs					
Other drugs	Ind.	Days	ST	Maint	AR
Other drugs Other immunosuppressive medication, specify:	Ind.	Days	ST	Maint	AR
-	Ind.	Days	ST	Maint	AR
Other immunosuppressive medication, specify:	Ind.	Days	ST	Maint	AR

Copyright  $\@ifnextchar{^}{\odot}$  2023 United Network for Organ Sharing. All rights reserved. Confidential - OPTN Use Only

UNOS Policies & Terms